Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Drug Discovery for Neurodegenerative Diseases: Challenges and Novel Biochemical Targets
Guest editors: Gabriel B. Britton, Mark A. Smith, George Perry, Kumar Sambamurti and K.S. Jagannatha Rao
Article type: Review Article
Authors: Decourt, Borisa | Sabbagh, Marwan N.a; b; *
Affiliations: [a] Banner Sun Health Research Institute, Haldeman Laboratory of Molecular Diagnostics and Therapeutics, Sun City, AZ, USA | [b] Banner Sun Health Research Institute, Director of the Cleo Roberts Center for Clinical Research, Sun City, AZ, USA
Correspondence: [*] Correspondence to: Marwan N. Sabbagh, Banner Sun Health Research Institute, 10515 Santa Fe Drive, Sun City, AZ 85351, USA. Tel.: +1 623 875 6500; Fax: +1 623 876 5461. E-mails: [email protected] (M.N. Sabbagh), [email protected] (B. Decourt).
Abstract: The diagnosis of Alzheimer's disease (AD) relies principally on clinical criteria for probable and possible AD as defined by the NINCDS-ADRDRA. The field is desperately lacking of biological markers to assist with AD diagnosis and verification of treatment efficacy. According to the Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease, in order to qualify as a biomarker the sample in question must adhere to certain basic requirements, including the ability to: reflect AD pathology and differentiate it from other dementia with an 80% sensitivity; be reliable and reproducible; be easy to perform and analyze; remain relatively inexpensive. Beta secretases are crucial enzymes in the pathogenesis of AD. Given its primary role in brain amyloidogenesis and its ubiquitous expression, one may consider measuring peripheral BACE1 levels and activity as biomarkers of AD, like performed in the brain and cerebrospinal fluid. However, very little is known about the periphery and whether peripheral BACE1 is involved in AD pathogenesis or mirrors AD progression. Moreover, no investigation has focused on the possibility of monitoring peripheral BACE1 to assess the efficiency of BACE1 inhibitors during the course of clinical trials. Part of the problem may be attributed to the lack of sensitive molecular tools which are absolutely necessary to use BACE1 as a biomarker. In this review we evaluate the progress and feasibility of developing BACE1 as a biomarker for AD in different tissues.
Keywords: Alzheimer's disease, BACE1, β-secretase, biomarker, blood, brain, cerebrospinal fluid
DOI: 10.3233/JAD-2011-110017
Journal: Journal of Alzheimer's Disease, vol. 24, no. s2, pp. 53-59, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]